Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma

Figure 2 Plasma vascular endothelial growth factor levels in patients with hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy treatment. A: Vascular endothelial growth factor (VEGF) levels were significantly lower in hepatocellular carcinoma patients with stable disease + partial response than in those with progressive disease (P < 0.05); B: Patients with high VEGF levels (> 100) had higher platelet levels than those with low VEGF levels (≤ 100) (P < 0.05); C: Patients with high Von Willebrand factor antigen (VWF:Ag)/ADAMTS13 activity (ADAMTS13:AC) ratio (> 2.7) had higher VEGF levels than those with low VWF:Ag/ADAMTS13:AC ratio (≤ 2.7). VEGF: Vascular endothelial growth factor; SD: Stable disease; PR: Partial response; PD: Progressive disease; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: Ratio of VWF:Ag to ADAMTS13:AC.